Skip to main content

Table 1 Baseline characteristics of participants

From: Coronary artery calcification, cardiovascular events, and death: a prospective cohort study of incident patients on hemodialysis

Baseline Characteristics

Coronary calcification below median (n = 25)

Coronary calcification above median (n = 26)

Total (N = 51)

P value

Missing data

Age, y (mean; SD)

54.1 (12.7)

63.2 (12.7)

58.7 (13.4)

0.014

0

Gender, male (n; %)

15 (60)

21 (80)

36 (70.6)

0.104

0

Duration of HD, d (mean; SD)

144.6 (67.8)

145.8 (55.7)

145.2 (61.3)

0.065

0

Coronary calcification score (mean; SD)

102 (164.8)

2520.9 (1563.8)

1335 (1651)

<0.001

0

Calcium, mmol/L (mean; SD)

2.3 (0.2)

2.3 (0.3)

2.3 (0.2)

0.800

1

Phosphorus, mmol/L (mean; SD)

1.8 (0.4)

1.8 (0.6)

1.8 (0.5)

0.857

1

Albumin, g/L (mean; SD)

39.4 (2.9)

36.2 (5.2)

37.8 (4.5)

0.011

1

Alkaline phosphatase, U/L (mean; SD)

99.0 (51.9)

110.0 (44.5)

104.2 (48.2)

0.490

13

Glucose, mmol/L (mean; SD)

8.8 (7.2)

9.3 (6.9)

9.0 (7.0)

0.790

1

HbA1C (mean; SD)

0.07 (0.02)

0.07 (0.02)

0.07 (0.02)

0.716

28

C reactive protein, mg/L (mean; SD)

5.5 (8.2)

31.8 (46.1)

19.3 (35.7)

0.091

30

Intact PTH, pmol/L (mean; SD)

104.5 (129.0)

104.3 (83.0)

104.4 (108.8)

0.994

10

Uric acid, μmol/L (mean; SD)

380.4 (75.5)

372.8 (78.5)

376.6 (76.1)

0.750

9

URR (mean; SD)

65.4 (16.1)

66.2 (7.3)

65.8 (12.3)

0.834

2

Hemoglobin, g/L

112.76 (12.30)

119.69 (11.31)

116.29 (12.20)

0.041

0

Comorbidities

COPD (n; %)

9 (36 %)

6 (23 %)

15 (29.4)

0.311

0

Liver disease (n; %)

2 (8 %)

0 (0 %)

2 (3.9)

0.141

0

Diabetes (n; %)

13 (52 %)

18 (69 %)

31 (60.8)

0.208

0

Hypertension (n; %)

23 (92 %)

24 (92 %)

47 (92.2)

0.967

0

Systolic blood pressure, mmHg (mean; SD)

147.6 (23.2)

145.4 (22.7)

146.5 (22.8)

0.737

0

Diastolic blood pressure, mmHg (mean; SD)

78.8 (15.9)

80.2 (14.2)

79.5 (14.9)

0.742

0

Baseline Cardiovascular Disease

Myocardial infarction (n; %)

4 (16 %)

7 (27 %)

11 (21.6)

0.343

0

CABG (n; %)

2 (8 %)

3 (11 %)

5 (9.8)

0.671

0

Percutaneous coronary intervention (n; %)

1 (4 %)

5 (19 %)

6 (11.8)

0.091

0

Atrial fibrillation (n; %)

2 (8 %)

5 (19 %)

7 (13.7)

0.244

0

DVT (n; %)

5 (20 %)

0 (0 %)

5 (9.8)

0.016

0

Pulmonary embolism (n; %)

4 (16 %)

0 (0 %)

4 (7.8)

0.034

0

Cause of ESRD

 Glomerulonephritis (n; %)

11 (44 %)

2 (8 %)

13 (25.5)

0.003

0

 Polycystic kidney disease (n; %)

2 (8 %)

1 (4 %)

3 (5.9)

0.529

0

 Diabetes mellitus (n; %)

6 (24 %)

12 (46 %)

18 (35.3)

0.098

0

 Hypertension (n; %)

5 (20 %)

10 (38 %)

15 (29.4)

0.148

0

 Other (n; %)

1 (4 %)

1 (4 %)

2 (3.9)

0.977

0

Medications

Calcium carbonate (n; %)

17 (68 %)

18 69 %

35 (68.6)

0.925

0

Sevelamer (n; %)

1 (4 %)

0 (0 %)

1 (2.0)

0.303

0

Bisphosphonates (n; %)

1 (4 %)

0 (0 %)

1 (2.0)

0.303

0

Warfarin (n; %)

4 (16 %)

5 (19 %)

9 (17.6)

0.762

0

Alfacalcidol (n; %)

14 (56 %)

9 (35 %)

23 (45.1)

0.125

0

  1. HD hemodialysis, CABG coronary artery bypass grafting, DVT deep venous thrombosis, ESRD End-stage renal disease. Missing data 0-2 % with the exceptions of alkaline phosphatase (25 %), Hb:A1C ratio (55 %), C reactive protein (59 %), INR (29 %), iPTH (20 %), and uric acid (18 %)